Insomnia as a Risk for Depression: A Longitudinal Epidemiologic Study on a Japanese Rural Cohort

Isa Okajima, PhD; Yoko Komada, PhD; Takashi Nomura, MD, PhD; Kenji Nakashima, MD, PhD; and Yuichi Inoue, MD, PhD

Published: October 4, 2011

Article Abstract

Objectives: To determine (1) whether insomnia is a factor related to the presence or persistence of depression for 2 years in the Japanese population and (2) which component of insomnia is associated with the presence of depression for 2 years in a rural cohort.

Method: This is a community-based longitudinal study. Two thousand eight hundred twenty-five people aged 20 years or older were evaluated at baseline, and of those participants, 1,577 (56%) were reevaluated after 2 years. During both surveys, the participants were asked to describe demographic variables and to fill out self-rating scales of insomnia (Pittsburgh Sleep Quality Index [PSQI]) and depressive symptoms (Center for Epidemiologic Studies Depression Scale).

Results: The results of a multiple logistic regression analysis showed that depression (OR = 6.0; 95% CI, 4.4-8.0) and insomnia (OR = 2.1; 95% CI, 1.5-2.8) at baseline were significantly associated with the presence of depression at the follow-up. Most of the PSQI subscales, except for sleep duration and habitual sleep efficiency, were significantly associated (P < .01) with the presence of depression at the follow-up. In addition, the new appearance and repeated existence of depression at the follow-up were related to persistent insomnia (adjusted ORs = 7.0 and 3.3 [P < .001], respectively). A result of the receiver operating characteristic curve showed that persons with insomnia whose PSQI scores exceeded 8 points at the baseline were most likely to still have insomnia at the follow-up (cutoff point = 7.5).

Conclusions: On the basis of our results in a Japanese population, insomnia with high severity level could be a risk factor for the presence/persistence of depression in the long-term prognosis.

J Clin Psychiatry 2012; 73(3):377-383

Volume: 72

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...